Activated B lymphocytes and tumor cell lysate as an effective cellular cancer vaccine.

摘要: Cancer vaccines that utilize patient antigen-presenting cells to fight their own tumors have shown exciting promise in many preclinical studies, but proven quite challenging translate clinical feasibility. Dendritic typically been the cell of choice for such vaccine platforms, due ability endocytose antigens nonspecifically, and expression multiple surface molecules enhance antigen presentation. However, dendritic are present low numbers human peripheral blood must be matured culture before use vaccines. Mature B lymphocytes, contrast, relatively abundant blood, can quickly activated expanded overnight cultures. We devised an optimal stimulation cocktail engages receptor, CD40, TLR4 TLR7, activate from lysates recipient's tumor cells, precluding need known antigens. This (Bvac) improved overall survival B16F1 melanoma challenge, as well reduced size increased time appearance. Bvac upregulated presentation molecules, stimulated activation both CD4+ CD8+ T induced migration. provides alternative cellular strategy has considerable practical advantages translation settings.